Roffman Miller Associates’s Agile Therapeutics AGRX Stock Holding History

Roffman Miller Associates’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1	Closed	-$3	–	170
2023 Q2	$3	Buy	+1	New	+$5	﹤0.01%	165

Other funds holding AGRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Roffman Miller Associates's AGRX Position: Q3 2023 in Review

Roffman Miller Associates sold out of Agile Therapeutics (AGRX) in Q3 2023, closing a stake of 1 share — an estimated $3 sold.

Roffman Miller Associates first reported a position in AGRX in Q2 2023 and held it in 1 quarter. The position peaked at $3 in Q2 2023. 17 funds tracked by Wall St. Rank hold AGRX as of Q3 2023.

Roffman Miller Associates reported no remaining Agile Therapeutics position as of Q3 2023 after selling out during the quarter.
Roffman Miller Associates sold 1 Agile Therapeutics share in Q3 2023, an estimated $3.
Roffman Miller Associates first reported a position in Agile Therapeutics in Q2 2023 and held it in 1 quarter.
Roffman Miller Associates's Agile Therapeutics position peaked at $3 in Q2 2023.
17 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2023.

Based on Roffman Miller Associates's 13F filing for Q3 2023, filed 9 Nov 2023.